ALLR
Allarity Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$1.21
+4.31%Sep 15, 2026, 12:00 UTC
The Japan Patent Office granted Allarity Therapeutics a patent covering its stenoparib-specific Drug Response Predictor companion diagnostic.
Source:Sep 11, 2026, 12:00 UTC
Allarity Acquisition Corp., a newly formed SPAC affiliated with Allarity Therapeutics, publicly filed a Form S-1 registration statement with the SEC for a proposed initial public offering of its units.
Source:Aug 14, 2026, 00:00 UTC
Allarity Therapeutics reported its Q2 2026 financial results, with zero revenue, a net loss of $3.4 million, and diluted EPS of -$0.21, ending the quarter with $26.9 million in cash and restricted cash.
Jun 2, 2026, 00:00 UTC
Allarity Therapeutics, Inc. appointed Thomas H. Jensen as Chief Executive Officer, effective June 1, 2026, with compensation including a monthly fee, annual bonus capped at 60% of monthly fees, and severance of 12 months of the monthly fee upon termination for convenience.